607368-87-6 Usage
Description
1,2,5-Oxadiazol-3-amine,4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-(9CI) is a chemical compound that is a derivative of Aminofurazan. It is characterized by its unique structure, which includes an oxadiazole ring and an imidazo[4,5-c]pyridine moiety. 1,2,5-Oxadiazol-3-amine,4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-(9CI) has been found to possess potent inhibitory activity against MSK-1, a protein kinase involved in various cellular processes.
Uses
Used in Pharmaceutical Industry:
1,2,5-Oxadiazol-3-amine,4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-(9CI) is used as a potent MSK-1 inhibitor for the development of therapeutic agents targeting various diseases and conditions. Its inhibitory activity against MSK-1 makes it a promising candidate for the treatment of cancer, inflammatory disorders, and other conditions where MSK-1 plays a significant role in disease progression.
Used in Research Applications:
In addition to its potential therapeutic applications, 1,2,5-Oxadiazol-3-amine,4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-(9CI) is also used in research settings to study the role of MSK-1 in various biological processes. Its potent inhibitory activity allows researchers to investigate the effects of MSK-1 inhibition on cellular signaling pathways, gene expression, and other cellular functions, providing valuable insights into the mechanisms underlying various diseases and conditions.
Used in Drug Discovery and Development:
1,2,5-Oxadiazol-3-amine,4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-(9CI) serves as a valuable chemical probe in drug discovery and development efforts. Its potent MSK-1 inhibitory activity makes it a useful tool for identifying and optimizing new compounds with similar or improved properties, ultimately leading to the development of more effective therapeutic agents for the treatment of various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 607368-87-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,0,7,3,6 and 8 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 607368-87:
(8*6)+(7*0)+(6*7)+(5*3)+(4*6)+(3*8)+(2*8)+(1*7)=176
176 % 10 = 6
So 607368-87-6 is a valid CAS Registry Number.
607368-87-6Relevant articles and documents
Discovery of aminofurazan-azabenzimidazoles as inhibitors of rho-kinase with high kinase selectivity and antihypertensive activity
Stavenger, Robert A.,Cui, Haifeng,Dowdell, Sarah E.,Franz, Robert G.,Gaitanopoulos, Dimitri E.,Goodman, Krista B.,Hilfiker, Mark A.,Ivy, Robert L.,Leber, Jack D.,Marino Jr., Joseph P.,Oh, Hye-Ja,Viet, Andrew Q.,Xu, Weiwei,Ye, Guosen,Zhang, Daohua,Zhao, Yongdong,Jolivette, Larry J.,Head, Martha S.,Semus, Simon F.,Elkins, Patricia A.,Kirkpatrick, Robert B.,Dul, Edward,Khandekar, Sanjay S.,Yi, Tracey,Jung, David K.,Wright, Lois L.,Smith, Gary K.,Behm, David J.,Doe, Christopher P.,Bentley, Ross,Chen, Zunxuan X.,Hu, Erding,Lee, Dennis
, p. 2 - 5 (2007/10/03)
The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension. Despite many available treatments, hypertension remains a prevalent problem. In fact, some 30% of hypertensive patients are unable to reach their blood pressure goals. Thus, a new anti-hypertensive treatment, which acts on a broader patient population, would be an important addition to existing treatments. A number of vasoconstrictive agents, including angiotensin II, endothelin-1, and urotensin-II, exert their effect through RhoA and the downstream kinase Rho-kinase (ROCK1).1 Because of its central role in the control of smooth muscle contraction, inhibition of ROCK1 could lead to a more broadly efficacious anti-hypertensive agent.2 ROCK1 inhibitors have been shown to relax vascular smooth muscle and lower blood pressure in several animal models of hypertension.3 Therefore, we began an effort to identify potent ROCK1 inhibitors with pharmacokinetic profiles consistent with once daily oral dosing.
